167 related articles for article (PubMed ID: 2170008)
1. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of WEHI-3B D+ monomyelocytic leukemia cells by retinoic acid and aclacinomycin A.
Gamba-Vitalo C; Blair OC; Keyes SR; Sartorelli AC
Cancer Res; 1986 Mar; 46(3):1189-94. PubMed ID: 3455881
[TBL] [Abstract][Full Text] [Related]
4. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity and differentiating actions of adriamycin in WEHI-3B D+ leukemia cells.
Gamba-Vitalo C; Blair OC; Tritton TR; Lane PA; Carbone R; Sartorelli AC
Leukemia; 1987 Mar; 1(3):188-97. PubMed ID: 3669742
[TBL] [Abstract][Full Text] [Related]
6. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB
Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621
[TBL] [Abstract][Full Text] [Related]
8. WEHI-3B D+ Y1 leukemia cells as a model system to assess the induction of differentiation in vivo.
Gamba-Vitalo C; Carman MD; Sartorelli AC
Cancer Commun; 1989; 1(3):157-65. PubMed ID: 2561737
[TBL] [Abstract][Full Text] [Related]
9. [Cell differentiation action of 4'-epi-adriamycin in WEHI-3B myelomonocytic leukemia cells].
Kajigaya Y; Ikuta K; Sasaki H; Matsuyama S
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2409-15. PubMed ID: 1952960
[TBL] [Abstract][Full Text] [Related]
10. Role of vitamin D3 receptor in the synergistic differentiation of WEHI-3B leukemia cells by vitamin D3 and retinoic acid.
Li J; Finch RA; Sartorelli AC
Exp Cell Res; 1999 Jun; 249(2):279-90. PubMed ID: 10366427
[TBL] [Abstract][Full Text] [Related]
11. The role of DNA ploidy in the differentiation of WEHI-3B D- leukemia cells transfected with the granulocyte colony-stimulating factor receptor gene.
Li J; Koay DC; Sartorelli AC
Exp Cell Res; 1995 Aug; 219(2):579-88. PubMed ID: 7543855
[TBL] [Abstract][Full Text] [Related]
12. Novobiocin- and phorbol-12-myristate-13-acetate-induced differentiation of human leukemia cells associated with a reduction in topoisomerase II activity.
Constantinou A; Henning-Chubb C; Huberman E
Cancer Res; 1989 Mar; 49(5):1110-7. PubMed ID: 2537141
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Utsugi T; Mattern MR; Mirabelli CK; Hanna N
Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
[TBL] [Abstract][Full Text] [Related]
14. Identification of a repressor of the differentiation of WEHI-3B D- leukemia cells.
Li J; Finch RA; Xiao W; Sartorelli AC
Exp Cell Res; 1998 Jul; 242(1):274-84. PubMed ID: 9665825
[TBL] [Abstract][Full Text] [Related]
15. Altered DNA-cleavage activity of topoisomerase II from WEHI-3B leukemia cells with specific resistance to ciprofloxacin.
Pessina A; Raimondi A; Croera C; Acchini M; Mineo E; Foti P; Neri MG
Anticancer Drugs; 2001 Jun; 12(5):441-51. PubMed ID: 11395572
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: induction of vimentin gene expression.
Rius C; Zorrilla AR; Cabañas C; Mata F; Bernabeu C; Aller P
Mol Pharmacol; 1991 Apr; 39(4):442-8. PubMed ID: 1850089
[TBL] [Abstract][Full Text] [Related]
17. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
18. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Rappa G; Lorico A; Sartorelli AC
Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
[TBL] [Abstract][Full Text] [Related]
19. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
20. Changes in nuclear protein kinase C-delta holoenzyme, its catalytic fragments, and its activity in polyomavirus-transformed pyF111 rat fibroblasts while proliferating and following exposure to apoptogenic topoisomerase-II inhibitors.
Dal Pra I; Whitfield JF; Chiarini A; Armato U
Exp Cell Res; 1999 May; 249(1):147-60. PubMed ID: 10328962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
